Cluster Headache Syndrome — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for cluster headache syndrome. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
6
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Cluster Headache Syndrome

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

GSK 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating cluster headache syndrome. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
30
1
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Imitrex
SUMATRIPTAN
 GSK 6 63 — 2030-06-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11337962 Imitrex method of use 76 2030-06-16
9974770 Imitrex method of use 68 2030-06-16
10603305 Imitrex method of use 68 2030-06-16
9610280 Imitrex method of use 68 2030-06-16
9211282 Imitrex method of use 68 2031-07-19
12090139 Imitrex formulation 61 2030-06-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12090139 Imitrex formulation 61 2030-06-16
9211282 Imitrex method of use 68 2031-07-19
9974770 Imitrex method of use 68 2030-06-16
10603305 Imitrex method of use 68 2030-06-16
9610280 Imitrex method of use 68 2030-06-16
11337962 Imitrex method of use 76 2030-06-16

Related